Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

After treatment with a GLP-1 RA, a person who has lost weight may ... Dermatologists may also be helpful, as they’re knowledgeable about the structure and function of the skin, as well as ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).

No significant differences were seen in the odds of postoperative pneumonia between GLP-1 RA users and nonusers in an adjusted analysis (odds ratio, 0.78; 95% confidence interval, 0.57 to 1.06; P ...

using its long-acting GLP-1 Receptor Agonist [GLP-1 RA] for the treatment of patients with obesity. It is currently in the process of treating obesity patients using the very same drug in an ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.